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Abstract
Eating disorders and related symptoms occur during midlife; however, little is known about their 
etiology. It has been hypothesized that perimenopause represents a window of vulnerability for the 
development or exacerbation of eating disorder symptomatology because, like puberty, 
perimenopause is a period of reproductive hormone change. We compared symptoms of bulimia 
nervosa (bulimic symptomatology) assessed via mean scores on a self-report questionnaire in 
premenopausal and perimenopausal women. We also examined the association between hormone 
concentrations (reproductive/appetite) and bulimic symptomatology. No mean differences in 
bulimic symptomatology were observed between premenopause and perimenopause. However, 
there was a significant positive association between leptin and binge eating. Although no 
significant associations between reproductive hormones and bulimic symptomatology were 
observed, additional research is needed to provide definitive information. It is essential to learn 
more about the etiology of eating disorders and related symptomatology across the lifespan in 
order to develop age-relevant treatment and prevention programs.
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Bulimic symptomatology can occur at all ages, including midlife (Elran-Barak et al., 2015; 
Gagne et al., 2012; Mangweth-Matzek, Hoek, Rupp, Kemmler, Pope, et al., 2013). One 
study reported that 13.3% of a sample of women ages 50 and older endorsed at least one 
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eating disorder symptom (Gagne, et al., 2012). For example, binge eating was reported to 
occur in 3% to 11% of women at midlife whereas the prevalence of purging was reported 
between 8% to 13.4% (Gagne, et al., 2012; Marcus, Bromberger, Wei, Brown, & Kravitz, 
2007). Women in midlife, like those during adolescence and adulthood, also report 
significant body dissatisfaction, weight concerns, and dissatisfaction with their overall 
appearance. (Gagne, et al., 2012; Marcus, et al., 2007; Runfola et al., 2013). Because 
reproductive hormone changes during puberty play a role in the risk for bulimic symptoms 
in adolescent girls (Klump, 2013), it is reasonable to postulate the reproductive hormone 
changes that occur during perimenopause may also increase risk (Baker & Runfola, 2016). 
However, this area of inquiry remains largely unexplored.
Of the reproductive hormones, estrogen appears to have the most significant role in risk for 
bulimic symptoms (Baker, Girdler, & Bulik, 2012). In women with bulimia nervosa (BN), 
binge eating and purging are exacerbated during the mid-luteal and pre-menstrual phases of 
the menstrual cycle when estrogen levels are low (Edler, Lipson, & Keel, 2007; Lester, Keel, 
& Lipson, 2003). In healthy women, decreased levels of estrogen during the menstrual cycle 
are associated with emotional eating (i.e., eating in response to negative emotions), weight 
preoccupation, and body image dissatisfaction (Carr-Nangle, Johnson, Bergeron, & Nangle, 
1994; Hildebrandt et al., 2014; Jappe & Gardner, 2009; Klump, Keel, Culbert, & Edler, 
2008). Taken together with the role estrogen has in risk for bulimic symptoms during 
adolescence (Klump, 2013), the associations between estrogen levels and eating disorder 
symptomatology during the menstrual cycle in women with and without BN suggest that 
periods of hormonal fluctuation may be a vulnerable time for risk and exacerbation of 
bulimic symptomatology. Thus, it is expected that the unpredictable hormonal fluctuations 
occurring during perimenopause may also increase vulnerability for the development of 
bulimic symptomatology during midlife (Baker & Runfola, 2016).
To date, one study has indirectly examined the association between hormone fluctuation and 
eating disorder symptomatology at midlife by comparing the prevalence of combined eating 
disorder diagnoses in midlife women who were pre-, peri-, and post-menopause. 
Perimenopause involves inconsistent and rapidly fluctuating levels of estrogen, whereas 
post-menopause marks the complete cessation of menstruation and consistently low levels of 
estrogen (Santoro & Randolph, 2011). Mangweth-Matzek and colleagues (2013) found that 
perimenopausal women reported a significantly higher prevalence of eating disorders, 
determined via a self-report questionnaire, compared with premenopausal women (9% 
versus 2%) (Mangweth-Matzek, Hoek, Rupp, Kemmler, Pope Jr, et al., 2013). Although this 
study was limited by having small numbers of women with an eating disorder, midlife may 
be a potential time of risk for eating disorders and this risk may be associated with the 
hormonal fluctuations that occur with perimenopause.
Research has also shown an association between appetite hormones and eating disorders, 
specifically binge-eating disorder (BED) and BN. For example, adiponectin and leptin are 
appetite-regulatory hormones that can act as an appetite-suppressant that show associations 
with both such that adiponectin is decreased in adults with BED and BN, albeit associations 
with BN are somewhat inconsistent (Khalil & El Hachem, 2014). On the other hand, leptin 
is increased in adults with BED and BN (Adami, Campostano, Cella, & Scopinaro, 2002; 
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Monteleone, Di Lieto, Tortorella, Longobardi, & Maj, 2000). Further, in regard to leptin 
specifically, estrogen appears to play a role in its functionality such that estrogen increases 
sensitivity to the appetite suppressant effects of leptin (Asarian & Geary, 2006). Therefore, 
the association between reproductive hormones and binge eating-related eating disorders 
may be mediated via appetite hormones.
With inpatient eating disorder admissions for women ages 35 and over on the rise (Wiseman, 
Sunday, Klapper, Harris, & Halmi, 2001), understanding the risk and protective factors for 
eating disorder symptomatology in this population is of growing clinical concern. To date, 
the associations between estrogen and appetite hormone concentrations and eating disorder 
symptomatology, specifically bulimic symptoms, during midlife have not been examined. 
Therefore, the goals of this study were two-fold: 1) compare bulimic symptomatology in 
premenopausal and perimenopausal women, hypothesizing that, similar to previous research, 
perimenopausal women will exhibit increased bulimic symptomatology compared with 
premenopausal women; and 2) explore, for the first time to our knowledge, the association 
between reproductive (estrogen, testosterone, follicle-stimulating hormone) and appetite 
hormones (leptin, adiponectin) and bulimic symptomatology in women in midlife.
Material and Methods
Participants
Participants included a subsample of women from the multisite Study of Women’s Health 
Across the Nation (SWAN), who participated in an ancillary mental health study (MHS), in 
which psychiatric information was collected. Detailed information about SWAN can be 
found elsewhere (Gold et al., 2000). In brief, women were eligible for the study if they were 
42–52 years old, were pre- or early peri- menopausal, not using exogenous hormones, had 
an intact uterus, and self-identified with one of the site’s designated racial/ethnic groups.
The SWAN MHS is an ancillary study of the larger parent SWAN study and included 
women at the Pittsburgh, Chicago, and New Jersey SWAN sites who were able to particpate 
in a psychiatric interview within 9 months of the baseline assessment. The current sample 
includes only women from the Pittsburgh (n = 366) and Chicago (n = 20) sites who were 
assessed at the first annual visit and completed an eating behavior questionnaire. There were 
not sufficient resources at the Chicago and New Jersey sites to continue conducting 
psychiatric interviews after baseline on any but a small number of participants. Previous 
comparisons among the sites indicated the sites were similar on demographic, psychosocial, 
perceived health variables, and current depressive symptoms (Marcus, Bromberger, Wei, 
Brown, & Kravitz, 2007).
As part of the MHS, participants completed a self-report questionnaire on bulimic 
symptomatology during the first or second annual visit. This questionnaire was only 
completed by the SWAN MHS participants. We included only those women who completed 
the measure at their first annual visit (n = 386). No significant differences on baseline 
measures of education, income, or body mass index (BMI) were observed between those 
women who completed the questionnaire and those who did not (Marcus, et al., 2007). 
However, at Pittsburgh, African American women were less likely to complete the 
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questionnaire than were Caucasian women, and, in Chicago, women who completed the 
questionnaire were less likely to report difficulty paying for basic necessities (Marcus, et al., 
2007).
The current sample also includes a subset of SWAN MHS participants who had appetite 
hormone data available from another ancillary study. This subset of individuals were chosen 
based on depression status. Specifically, participants having a lifetime history of major 
depression on the Structured Clinical Interview for DSM-IV Disorders (SCID; (First, 
Spitzer, Gibbon, & Williams, 1997) were selected as cases and matched on age and ethnicity 
with women who had no history of major depression. Therefore, only a subset of the MHS 
sample (65%, n = 227) were included in this separate research protocol and have appetite 
hormone data available.
Informed consent was obtained from all study participants. SWAN site Institutional Review 
Boards approved all study procedures and protocols. The University of North Carolina 
Institutional Review Board approved this study.
Measures
Bulimic Symptomatology—The Bulimia Test-Revised (BULIT-R) was used to examine 
bulimic symptomatology (Thelen, Farmer, Wonderlich, & Smith, 1991). The BULIT-R is a 
28-item self-report questionnaire that focuses on symptoms of BN in clinical and nonclinical 
populations. Items are scored on a 1–5 scale with higher scores reflecting increased 
symptomatology. For analyses, we used the BULIT-R total score, which is a summation of 
all items. In an earlier analysis, two additional subscales were created in order to capture 
specific BN symptoms including binge eating and body dissatisfaction (Marcus, et al., 
2007).1 Each subscale represents a summation of all items reflecting behaviors and 
characteristics related to binge eating or body dissatisfaction, respectively. The internal 
reliability of the total score (alpha = 0.93) and binge eating (alpha = 0.91) and body 
dissatisfaction subscales (alpha = 0.83) were good. All BULIT-R scales were log-
transformed prior to analysis to account for a positive skew.
Menopause status—Menopause status was based on menstrual bleeding patterns during 
the previous 12 months. At study entry, women were either premenopause or early 
perimenopause due to eligibility requirements. At the first annual visit women were still 
either premenopausal or perimenopausal; none were postmenopausal. Premenopause was 
defined as having a menstrual period in the past 3 months with no change in regularity in the 
past 12 months. Perimenopause was defined as having a menstrual period in the past 3 
months with change in regularity over the past 12 months or having no menstrual period 
within the last 3 months but some menstrual bleeding in the previous 12 months. For the 
current study, participants reporting surgical menopause or hormone use were excluded.
Reproductive hormones—Blood draws were performed following an overnight fast 
during days 2–5 of the follicular phase of the menstrual cycle at the first annual visit. Blood 
1The binge eating subscale included the following questions from the BULIT-R: items 1, 2, 3, 7, 8, 9, 11, 14, 15, 17, 18, 19, 24, 25, 
26, and 27. The body dissatisfaction subscale included the following questions: items 4, 6, 10, 12, 20, 23, and 28.
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was refrigerated prior to centrifugation 1–2 hours after the draw, and the serum was 
aliquoted, frozen, and batched for shipment to a central laboratory. Samples were catalogued 
and assayed immediately upon arrival. All assays were performed on the ACS-180 
automated analyzer (Bayer Diagnostics Corporation, Tarrytown, NY) utilizing a double-
antibody chemiluminescent immunoassay with a solid phase anti-IgG immunoglobulin 
conjugated to paramagnetic particles, anti-ligand antibody, and competitive ligand labeled 
with dimethylacridinium ester (DMAE).
The estrogen (E2) assay modifies the rabbit anti-E2-6 ACS-180 immunoassay to increase 
sensitivity, with a LLD of 1.0 pg/mL. The testosterone (T) assay modifies the rabbit 
polyclonal anti-T ACS-180 immunoassay, with a LLD of 2.19 ng/dL. The follicle-
stimulating hormone (FSH) assay is a modification of a manual assay kit (Bayer 
Diagnostics) utilizing two monoclonal antibodies directed to different regions on the beta 
subunit, with a lower limit of detection (LLD) of 1.05 mIU/mL. Duplicate E2 assays were 
conducted with results reported as the arithmetic mean for each subject, with a coefficient of 
variation of 3–12%. All other assays were single determinations.
Appetite hormones—At the first annual visit, the SWAN blood collection protocol 
included a fasting blood draw for a specimen repository that is maintained at −80°C until 
processing. Serum leptin and adiponectin were determined spectrophotometrically using 
commercially available immunoassay kits and run according to manufacturer’s instructions. 
For leptin, the coefficient of variation for duplicate samples was 3.7%, and the lower limit of 
detection was 0.5 ng/ml. For adiponectin, the coefficient of variation was 5.4%, and the 
lower limit of detection was 0.78 ng/ml. As described above, both assays were completed as 
part of a separate research protocol at the Pittsburgh and Chicago SWAN sites and thus 
appetite hormone data were only available in a subset of the MHS sample. All reproductive 
and appetite hormone values were log-transformed prior to analysis.
Covariates—Age, race/ethnicity, education, and income were obtained during baseline 
visits. Additional covariates (i.e., BMI, history of major depression, physical activity, self-
reported overall health, income, and smoking status) were obtained during the first annual 
visit when the BULIT-R was completed. Education was categorized as no high school 
degree, completed high school or GED, some college, college graduate, or more than a 
college degree. For income, participants were provided with income ranges (<$10,000; 
$10,000–$19,999; $20,000–$34,999; $35,000–$49,999; $50,000–$74,999; $75,000–
$99,999; $100,000–$149,999; >=$150,000) and asked to identify their appropriate range.
At each visit, height and weight, obtained in street clothes without shoes, were measured and 
BMI (weight [kg]/height [m2]) was calculated. A current or past history of major depression 
was assessed with the SCID. To examine physical activity, participants were asked whether, 
compared with others, their physical activity level was: 1) much less; 2) somewhat less; 3) 
about the same; 4) somewhat more; or 5) much more. At each visit, participants were also 
asked to self-report their overall health (as poor, fair, good, very good, or excellent) and 
whether they regularly smoked cigarettes.
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Initially, we examined the association between the three BULIT-R scales and the 
aforementioned covariates of interest. Variables which had a significant association with the 
BULIT-R total score, binge-eating subscale, or body dissatisfaction subscale were included 
in respective analsyes. However, the MHS assessment site (i.e., Pittsburgh or Chicago), race/
ethnicity, and history of major depression (due to the oversampling of women with a history 
of major depression) were included as covariates in all analyses. All analyes were completed 
with the log transformed BULIT-R and reproductive and appetite hormone values.
Next, we completed an ANOVA, both with and without relevant covariates, to examine mean 
score differences in binge eating, body dissatisfaction, and the BULIT-R total score based on 
menopause status (pre- vs. peri-menopause) in the full sample, with premenopause women 
as the reference group. BULIT-R scales were included as the dependent variable and 
menopause status as the independent variable.
General linear models were used to evaluate the associations between bulimic 
symptomatology and the hormonal variables of interest. Models were conducted with the 
BULIT-R subscales as dependent variables and E2, T, FSH, leptin, and adiponectin as 
independent variables. We also included the following interactions: E2*leptin and 
leptin*adiponectin. Because the selection of participants for appetite hormone assay were 
based on case or control status for a history of major depression, modeling was completed in 
steps as we first wanted to document that the association between bulimic symptomatology 
and reproductive hormones was similar in the full sample and the subset of women chosen 
for appetite hormone assays.
First, associations were examined between bulimic symptomatology and reproductive 
hormones in the full sample (N = 386), excluding appetite hormones as independent 
variables (Model 1). This allowed us to assess the association between the BULIT-R 
subscales and reproductive hormones in the total sample. Second, associations were 
examined between bulimic symptomatology and reproductive hormones in the reduced 
sample of women with appetite hormone data (n = 227), again, excluding appetite hormones 
as independent variables (Model 2). This allowed us to assess the association between the 
BULIT-R subscales and reproductive hormones in the subset of women chosen for appetite 
hormone assay based on depression status—providing information as to whether there are 
similar associations between reproductive hormones and bulimic symptomatology in both 
the full and reduced samples. Last, we completed our full model of interest (Model 3), 
which included leptin and adiponectin as independent variables (in the reduced sample of 
women with appetite hormone data) and interactions of interest. Nonsignficant interactions 
were removed from modeling to ensure appropriate interpretation of main effects. All 
analyses were completed using SAS 9.2 (SAS Institute Inc, 2004) and p < .05 was 
considered significant.
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Sample characteristics are provided in Table 1. Thirty-two percent of the sample were 
African American (n = 125), and the mean age of participants at baseline was 45 years old. 
At the first annual visit, 29% (n = 100) of women were premenopause and the mean BMI 
was 29.2 kg/m2. According to World Health Organization BMI classification, approximately 
39% (n = 150) of women were obese, 31.4% (n = 121) overweight, 29% (n = 111) in the 
healthy range, and 1% (n = 4) of women were underweight. Finally, 35% (n =137) of the 
sample reported a lifetime history of major depressive disorder on the SCID. Initial analyses 
indicated that BMI and self-reported overall health status were significantly associated with 
the BULIT-R total score and the binge eating and body dissatisfaction subscales. Therefore, 
these covariates were included in the respective follow-up models.
No significant differences were observed between premenopausal and perimenopausal 
women on any of the BULIT-R subscales in the ANOVA models including and excluding 
relevant covariates—results were similar in both analyses. In the model excluding covariates 
we were able to calculate the sole effect of menopause status on bulimic symptomatology 
(Table 2). As can be seen, effect sizes indicated a small effect of menopause status for the 
BULIT-R scales.
No significant associations between E2, T, or FSH and the BULIT-R scales in either the full 
sample or the reduced sample were observed (Table 3; interactions were not significant and 
removed from the model) suggesting similar null associations in both samples. BMI was the 
only variable significantly associated with the BULIT-R total score, binge eating, and body 
dissatisfaction subscales in both models. The results were similar in the final model (model 
3) including the reduced sample and including leptin and adiponectin as independent 
variables. However, leptin scores were significantly associated with binge eating and E2 
trended towards significance with body dissatisfaction (Table 4; interactions were not 
significant and removed from the model).
Discussion
Our aims were twofold: to further explore the reported association between perimenopause 
status and eating disorder symptomatology, specifically focusing on bulimic symptoms, and 
to examine, for the first time to our knowledge, the direct association between reproductive 
hormones, appetite hormones, and bulimic symptomatology during midlife. Contrary to our 
hypothesis and a previous report (Mangweth-Matzek, Hoek, Rupp, Kemmler, Pope Jr, et al., 
2013), we found no significant differences in bulimic symptomatology between pre- and 
peri- menopausal women. Two reasons may account for differing findings. First, the two 
studies used differing methods to assess eating disorder symptoms. The aforementioned 
study focused on combined eating disorder diagnoses assessed through a self-report 
questionnaire whereas the current report focused on a well-validated continuous measure of 
bulimic symptomatology. The difference in assessment measures used could have played a 
role in our null findings. However, although the previous study observed significant 
differences in self-reported eating disorder diagnoses between pre- and peri- menopause, 
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that study did not find significant differences in eating disorder dimensions assessed by the 
Eating Disorder Inventory (Mangweth-Matzek, Hoek, Rupp, Kemmler, Pope Jr, et al., 2013). 
Second, the BULIT-R focuses on symptomatology most relevant for BN, a diagnosis which 
is less common in midlife women compared with BED or eating disorder not otherwise 
specified (Elran-Barak, et al., 2015; Mangweth-Matzek, Hoek, Rupp, Kemmler, Pope Jr, et 
al., 2013). Thus, although speculative, the differences observed in eating disorder 
symptomatology between pre- and peri- menopause may only be present when these 
symptoms reach a threshold level and/or pertain to eating disorder diagnoses only 
characterized by binge eating (e.g., BED). This would align with the young adult findings 
that show binge eating has the strongest association with estrogen fluctuation (Baker, et al., 
2012).
In regression modeling, we observed similar associations in model 1 (the full sample) and 
model 2 (the reduced sample enriched with lifetime major depression cases and matched 
controls) between all independent variables, suggesting that the associations (and lack 
thereof) were the same in both samples. In both models, BMI was the only variable 
significantly associated with bulimic symptomatology. In model 3, which included all 
participants and all variables of interest, BMI remained significantly associated with all 
BULIT-R scales. However, additional patterns emerged.
Consistent with prior studies in women with BED (Monteleone, et al., 2000) but contrary to 
studies in young adults with BN (Bluher & Mantzoros, 2004), we observed a positive 
association between binge eating and leptin concentrations. Reasons for the disparate set of 
findings with BN may relate to several factors, including the higher prevalence of BED 
among midlife women (Elran-Barak, et al., 2015; Mangweth-Matzek, Hoek, Rupp, 
Kemmler, Pope, et al., 2013); leptin may increase over time in response to binge eating 
behaviors; the positive association between obesity and leptin; (Scarpace & Zhang, 2007) or 
increasing leptin levels across pre-, peri-, and post- menopause (Sowers et al., 2008).
A positive trend was also observed between E2 and body dissatisfaction. This is in line with 
Mangweth-Matzek and colleagues (2013), who observed increased feelings of fatness in 
perimenopausal women compared with premenopausal women. However, we did not 
observe increased body dissatisfaction during perimenopause. Regardless, it is conceivable 
that as E2 concentrations fluctuate and change during midlife, these changes may impact 
body fat accumulation and waist circumference (Davis et al., 2012; Wildman et al., 2012), 
which in turn may impact body dissatisfaction—regardless of menopause stage. Further 
investigation is warranted to examine this notion. Until then, our trend-level finding must be 
interpreted with caution.
Although our findings do not provide evidence for a strong, direct association among 
reproductive hormones, appetite hormones, and bulimic symptomatology during midlife, 
results must be considered preliminary and within the context of study limitations. First, our 
sample was somewhat small and not a true community sample. A portion of the sample was 
enriched with individuals selected based on lifetime major depression status. Thus, our 
findings may not be representative of women in midlife as a whole. Second, we did not 
assess current eating disorder diagnosis. As noted previously, perimenopausal women may 
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have a significantly higher prevalence of threshold eating disorders than premenopausal 
women, but because we focused on symptoms versus diagnosis this significant difference 
may not have been observed. Diagnostic information would have allowed us to reproduce 
the study by Mangweth-Matzek and colleagues (2013) and permitted the evaluation of a 
direct association between estrogen and eating disorder diagnosis. Finally, we only obtained 
one measurement of estrogen. In the young adult literature, studies have obtained multiple 
measurements of estrogen, exploring the impact of changing estrogen levels on eating 
disorder symptomatology. We may have observed significant associations if we were able to 
examine within-person change in estrogen levels as has been observed in young adult 
samples across the menstrual cycle.
Given the strong and consistent evidence of the role of puberty and reproductive hormones 
in the vulnerability for bulimic symptoms during adolescence and young adulthood, further 
research examining the role of hormones in the etiology of bulimic symptoms at midlife is 
warranted. Puberty and perimenopause may represent complementary periods of risk for 
bulimic symptomatology. Pre-puberty and menopause bookmark a women’s reproductive 
cycle as hypoestrogenic states (i.e., estrogen deficiency), and puberty and perimenopause are 
the transitions out of or into these states, respectively. Moreover, not only are hormonal 
changes occurring at both stages, but both often have additional significant psychological 
(e.g., increased risk for depression), social (e.g., life transitions), and physical (change in 
adiposity, weight gain) changes. Given the reported increase of eating disorders, particularly 
binge eating-related disorders, in women in midlife and in the number of midlife women 
seeking treatment for these eating disorders, it is critical that we learn more about the 
etiology and risk for eating disorders and related-symptoms during this developmental stage.
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